100
Views
1
CrossRef citations to date
0
Altmetric
Case Report

Prolonged course of Fosfomycin-Trometamol for chronic prostatitis: an unknown good option

Pages 344-345 | Received 18 Feb 2021, Accepted 17 May 2021, Published online: 01 Jun 2021

References

  • Kwan ACF, Beahm NP. Fosfomycin for bacterial prostatitis: a review. Int J Antimicrob Agents. 2020;56:106106.
  • Bergogne-Bérézin E. Fosfomycin and derivatives. In: Bryskier A, editor. Antimicrobial agents. Washington: ASM Press; 2005. p. 972–982.
  • Gardiner BJ, Mahony AA, Ellis AG, et al. Is Fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis? Clin Infect Dis. 2014;58(4):e101–e105.
  • Karaiskos I, Galani L, Sakka V, et al. Oral fosfomycin for the treatment of chronic bacterial prostatitis. J Antimicrob Chemother. 2019;1(74):1430–1437.
  • Mueller L, Cimen C, Poirel L, et al. Prevalence of fosfomycin resistance among ESBL-producing Escherichia coli isolates in the community, Switzerland. Eur J Clin Microbiol Infect Dis. 2019;15(38):945–949.
  • Cho YH, Jung S, Il Chung HS, et al. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin. Int Urol Nephrol. 2015;31(47):1059–1066.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.